Hybio Pharmaceutical (300199) - Net Assets

Latest as of September 2025: CN¥666.08 Million CNY ≈ $97.47 Million USD

Based on the latest financial reports, Hybio Pharmaceutical (300199) has net assets worth CN¥666.08 Million CNY (≈ $97.47 Million USD) as of September 2025. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (CN¥3.17 Billion ≈ $463.97 Million USD) and total liabilities (CN¥2.50 Billion ≈ $366.50 Million USD). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. Check Hybio Pharmaceutical (300199) asset resilience to evaluate the company's liquid asset resilience ratio.

Key Net Assets Metrics

Metric Value
Current Net Assets CN¥666.08 Million
% of Total Assets 21.01%
Annual Growth Rate 15.88%
5-Year Change -64.42%
10-Year Change -77.36%
Growth Volatility 108.66

Hybio Pharmaceutical - Net Assets Trend (2007–2024)

This chart illustrates how Hybio Pharmaceutical's net assets have evolved over time, based on quarterly financial data. Also explore Hybio Pharmaceutical asset portfolio for the complete picture of this company's asset base.

Annual Net Assets for Hybio Pharmaceutical (2007–2024)

The table below shows the annual net assets of Hybio Pharmaceutical from 2007 to 2024. For live valuation and market cap data, see Hybio Pharmaceutical stock valuation.

Year Net Assets Change
2024-12-31 CN¥597.05 Million
≈ $87.37 Million		 -23.77%
2023-12-31 CN¥783.21 Million
≈ $114.61 Million		 -39.61%
2022-12-31 CN¥1.30 Billion
≈ $189.78 Million		 -21.30%
2021-12-31 CN¥1.65 Billion
≈ $241.15 Million		 -1.78%
2020-12-31 CN¥1.68 Billion
≈ $245.53 Million		 -24.86%
2019-12-31 CN¥2.23 Billion
≈ $326.77 Million		 -34.16%
2018-12-31 CN¥3.39 Billion
≈ $496.31 Million		 -12.69%
2017-12-31 CN¥3.88 Billion
≈ $568.47 Million		 +7.77%
2016-12-31 CN¥3.60 Billion
≈ $527.46 Million		 +36.68%
2015-12-31 CN¥2.64 Billion
≈ $385.92 Million		 +103.47%
2014-12-31 CN¥1.30 Billion
≈ $189.67 Million		 +15.29%
2013-12-31 CN¥1.12 Billion
≈ $164.51 Million		 +10.65%
2012-12-31 CN¥1.02 Billion
≈ $148.68 Million		 +4.09%
2011-12-31 CN¥976.09 Million
≈ $142.83 Million		 +440.51%
2010-12-31 CN¥180.59 Million
≈ $26.43 Million		 +41.37%
2009-12-31 CN¥127.74 Million
≈ $18.69 Million		 +28.74%
2008-12-31 CN¥99.23 Million
≈ $14.52 Million		 +103.76%
2007-12-31 CN¥48.70 Million
≈ $7.13 Million		 --

Equity Component Analysis

This analysis shows how different components contribute to Hybio Pharmaceutical's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.

Equity Composition Insights

  • Retained earnings have decreased by 8180.4% over the analyzed period, potentially due to dividend distributions or operating losses.

Current Equity Component Breakdown (December 2024)

Component Amount Percentage
Common Stock CN¥883.24 Million 152.64%
Other Comprehensive Income CN¥41.22 Million 7.12%
Other Components CN¥1.45 Billion 250.22%
Total Equity CN¥578.63 Million 100.00%

Hybio Pharmaceutical Competitors by Market Cap

The table below lists competitors of Hybio Pharmaceutical ranked by their market capitalization.

Company Market Cap
Shenzhen Colibri Technologies Co Ltd
SHE:002957
 $2.68 Billion
Seadrill Limited
NYSE:SDRL
 $2.68 Billion
Sinocelltech Group Ltd
SHG:688520
 $2.68 Billion
Scorpio Tankers Inc.
F:S0QA
 $2.68 Billion
An Hui Wenergy Co Ltd
SHE:000543
 $2.68 Billion
Worthington Industries Inc
NYSE:WOR
 $2.68 Billion
VGP NV
BR:VGP
 $2.68 Billion
Harley-Davidson Inc
NYSE:HOG
 $2.68 Billion

Equity Growth Attribution

This analysis shows how different factors contributed to changes in Hybio Pharmaceutical's equity between the two most recent reporting periods.

Equity Growth Insights

  • From 2023 to 2024, total equity changed from 758,803,660 to 578,626,837, a change of -180,176,823 (-23.7%).
  • Net loss of 173,654,017 reduced equity.
  • Dividend payments of 111,745,664 reduced retained earnings.
  • Other comprehensive income increased equity by 1,954,587.
  • Other factors increased equity by 103,268,271.

Equity Change Factors (2023 to 2024)

Factor Impact Contribution
Net Income CN¥-173.65 Million -30.01%
Dividends Paid CN¥111.75 Million -19.31%
Other Comprehensive Income CN¥1.95 Million +0.34%
Other Changes CN¥103.27 Million +17.85%
Total Change CN¥- -23.74%

Book Value vs Market Value Analysis

This analysis compares Hybio Pharmaceutical's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.

Valuation Insights

  • Current price-to-book ratio: 31.12x
  • The company is trading at a significant premium to its book value, suggesting the market values its earnings potential, brand, or other intangibles highly.
  • The price-to-book ratio has decreased from 199.00x to 31.12x over the analyzed period, indicating reduced market premium.

Historical Price-to-Book Ratios

Date Book Value per Share Market Price P/B Ratio
2007-12-31 CN¥0.10 CN¥20.74 x
2008-12-31 CN¥0.21 CN¥20.74 x
2009-12-31 CN¥0.22 CN¥20.74 x
2010-12-31 CN¥0.30 CN¥20.74 x
2011-12-31 CN¥1.30 CN¥20.74 x
2012-12-31 CN¥1.24 CN¥20.74 x
2013-12-31 CN¥1.38 CN¥20.74 x
2014-12-31 CN¥1.44 CN¥20.74 x
2015-12-31 CN¥2.94 CN¥20.74 x
2016-12-31 CN¥4.07 CN¥20.74 x
2017-12-31 CN¥4.12 CN¥20.74 x
2018-12-31 CN¥3.68 CN¥20.74 x
2019-12-31 CN¥2.52 CN¥20.74 x
2020-12-31 CN¥1.85 CN¥20.74 x
2021-12-31 CN¥1.79 CN¥20.74 x
2022-12-31 CN¥1.44 CN¥20.74 x
2023-12-31 CN¥0.86 CN¥20.74 x
2024-12-31 CN¥0.67 CN¥20.74 x

Capital Efficiency Dashboard

This dashboard shows how efficiently Hybio Pharmaceutical utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.

Capital Efficiency Insights

  • Current Return on Equity (ROE): -30.01%
  • The company may be facing challenges in efficiently utilizing shareholder equity.
  • DuPont Analysis Breakdown:
  • • Net Profit Margin: -29.42%
  • • Asset Turnover: 0.20x
  • • Equity Multiplier: 5.20x
  • Recent ROE (-30.01%) is below the historical average (-1.87%), suggesting potential challenges in capital efficiency.

Historical Capital Efficiency Metrics

Year Return on Equity Net Profit Margin Asset Turnover Equity Multiplier Economic Value Added
2007 31.28% 27.10% 0.97x 1.20x CN¥10.36 Million
2008 20.01% 25.67% 0.57x 1.38x CN¥9.94 Million
2009 27.69% 38.15% 0.51x 1.43x CN¥22.59 Million
2010 29.26% 43.34% 0.57x 1.18x CN¥34.79 Million
2011 8.24% 49.37% 0.16x 1.06x CN¥-17.13 Million
2012 8.84% 40.28% 0.20x 1.11x CN¥-11.81 Million
2013 11.56% 43.11% 0.23x 1.15x CN¥17.51 Million
2014 13.24% 40.90% 0.25x 1.31x CN¥41.95 Million
2015 11.58% 39.74% 0.22x 1.34x CN¥41.61 Million
2016 8.10% 34.14% 0.19x 1.24x CN¥-68.53 Million
2017 8.49% 26.46% 0.24x 1.36x CN¥-58.76 Million
2018 -10.05% -26.95% 0.22x 1.67x CN¥-679.95 Million
2019 -39.71% -144.05% 0.13x 2.12x CN¥-1.11 Billion
2020 -37.22% -84.44% 0.18x 2.46x CN¥-773.18 Million
2021 1.94% 4.19% 0.19x 2.47x CN¥-127.66 Million
2022 -29.16% -52.61% 0.20x 2.84x CN¥-497.61 Million
2023 -67.72% -119.12% 0.13x 4.32x CN¥-589.76 Million
2024 -30.01% -29.42% 0.20x 5.20x CN¥-231.52 Million

Industry Comparison

This section compares Hybio Pharmaceutical's net assets metrics with peer companies in the Drug Manufacturers - Specialty & Generic industry.

Industry Context

  • Industry: Drug Manufacturers - Specialty & Generic
  • Average net assets among peers: $1,347,197,696
  • Average return on equity (ROE) among peers: 4.46%

Peer Company Comparison

Company Net Assets Return on Equity Debt-to-Equity Market Cap
Hybio Pharmaceutical (300199) CN¥666.08 Million 31.28% 3.76x $2.68 Billion
Shenzhen Neptunus Bioengineering Co Ltd (000078) $2.84 Billion -41.97% 9.13x $1.22 Billion
Anhui Fengyuan Pharmaceutical Co Ltd (000153) $638.89 Million 0.88% 0.70x $438.59 Million
Shan Dong Dong-E E-Jiao Co Ltd (000423) $1.05 Billion 10.46% 0.19x $5.18 Billion
Livzon Pharmaceutical Group Inc (000513) $1.07 Billion 3.83% 0.46x $2.81 Billion
Wedge Industrial Co Ltd (000534) $1.29 Billion 11.69% 1.47x $2.95 Billion
Yunnan Baiyao Group Co Ltd (000538) $35.11 Million 18.13% 0.80x $13.85 Billion
Hainan Haiyao Co Ltd (000566) $5.08 Billion 1.71% 1.08x $949.23 Million
Tus Pharmaceutical Group Co Ltd (000590) $141.91 Million 11.01% 0.32x $391.07 Million
Northeast Pharmaceutical Group Co Ltd (000597) $994.58 Million 2.01% 2.11x $1.03 Billion
Jilin Aodong Pharmaceutical Group Co Ltd (000623) $332.48 Million 26.89% 0.68x $3.30 Billion

About Hybio Pharmaceutical

SHE:300199 China Drug Manufacturers - Specialty & Generic
Market Cap
$2.68 Billion
CN¥18.32 Billion CNY
Market Cap Rank
#5281 Global
#1049 in China
Share Price
CN¥20.74
Change (1 day)
-1.14%
52-Week Range
CN¥13.62 - CN¥29.95
All Time High
CN¥29.95
Categories
Companies in China Drug Manufacturers - Specialty & Generic
About

Hybio Pharmaceutical Co., Ltd. engages in the research, development, production, and marketing of peptide and oligonucleotide drugs in China and internationally. The company offers finished dosage form (FDF) products for obstetrics and gynecology, haemostatic agent, digestive tract and metabolic systems, immune system modulation, cardiovascular, diabetes mellitus, and osteoporosis, as well as dis… Read more